Almond FinTech provides a programmable, multi-chain FX routing orchestration engine for corporate treasuries and money transmitters. This intelligence layer leverages blockchains and stablecoins to automate and optimize treasury payouts, consistently delivering superior FX rates. The platform integrates routing, automation, and analytics into a compliance-first stack for efficient global money movement.

Aphea.Bio develops natural biocontrol and biostimulant products for agriculture using its APEXbio™ R&D platform. This platform accelerates the discovery of novel microbial solutions for crop protection and enhancement. The company provides advanced biological products, including biostimulants and biofungicides, supporting sustainable farming practices.

ATB Therapeutics develops targeted antibody therapies using its proprietary antibody payload technology to treat hematological malignancies and autoimmune diseases. The company addresses the need for effective treatments in oncology and autoimmune disorders by leveraging a plant-based manufacturing platform to enhance therapeutic delivery.

AXI Mobility offers an electric vehicle (EV) platform for ride-hailing, food delivery, and package delivery, offsetting carbon emissions with each trip. The platform plants trees based on user activity, turning everyday transportation into environmental action.

Brightflow AI is a financial intelligence platform that utilizes AI-driven analytics to provide real-time cash flow management and forecasting tools for businesses. It enables users to track financial data across multiple channels, assess their business creditworthiness, and access tailored growth capital options to enhance financial decision-making.

This company provides an AI platform designed to assist enterprise compensation teams with pay decisions using proprietary market data. The platform features AI agents that analyze market trends for compensation analysts and scale expertise for HR and recruiting stakeholders. It integrates with existing HR infrastructure to ensure accurate, real-time compensation alignment with company strategy.

e-peas S.A. develops ultra-low-power semiconductor solutions, including energy harvesting modules and microcontrollers, that enable devices to operate autonomously by harnessing ambient energy sources. This technology eliminates the need for battery replacements, addressing the challenges of frequent battery disposal and the maintenance of wireless sensor networks.

ExeVir develops novel antibody therapies utilizing a modular platform based on camelid antibody fragments (VHH) for infectious disease control. This technology creates stable, cost-effective therapeutic compounds capable of binding multiple conserved epitopes on pathogens. The company is advancing a pipeline focused initially on COVID-19 and dengue to address public health threats, particularly for vulnerable patient populations.

Generare operates an industrial‑scale platform that extracts, purifies, identifies, and annotates previously unread microbial metabolites directly from their natural contexts, creating high‑quality molecular data that have never been seen by AI models or researchers. By unlocking the 97% of microbial chemistry hidden from traditional libraries, the company supplies pharmaceutical and biotech partners with novel, evolution‑derived scaffolds for rapid development of first‑in‑class drug candidates across areas such as antibiotics and oncology.

Ligo Biosciences builds deep‑learning generative models that design novel enzymes for the chemical industry. By training on natural protein sequences and structures, their platform creates catalysts that can accelerate and scale the synthesis of materials and products, reducing reliance on traditional chemical processes. The company monetizes access to its enzyme‑design platform through licensing and service agreements with industrial partners seeking more efficient biocatalytic solutions.

MZR Neurotech develops an in-ear electroencephalogram (EEG) sensor that accurately measures sleep patterns and brain activity. This technology provides users with detailed insights into their sleep quality, enabling better management of sleep-related issues.

Node provides a 1-Click commerce platform that enables merchants to facilitate transactions without requiring user sign-ups, thereby enhancing customer engagement and reducing drop-off rates. By delivering personalized offers and experiences while ensuring 100% privacy, Node transforms guest users into loyal customers, streamlining the shopping process and increasing conversion rates.

NOVA is a platform that connects creative professionals with job opportunities by allowing users to showcase their portfolios and post job listings tailored to specific project needs. It addresses the challenge of finding qualified talent quickly in the creative industry, having generated over $10 million for creatives and facilitated 17,000 job postings across more than 500 cities globally.

Nuclidium provides a cyclotron‑produced copper‑61/‑67 radiopharmaceutical platform that combines PET imaging and targeted beta‑therapy within a single chelator‑ligand framework. The matched isotopic pair enables accurate dosimetry, streamlined manufacturing, and lower per‑dose costs, expanding access for nuclear medicine and oncology departments.

O is developing an IoT device that visualizes the human circadian clock to enhance individual and organizational performance through data-driven insights. The platform provides actionable recommendations based on sleep data, addressing productivity issues and mental health risks within teams.

Oly provides a centralized platform for luxury fashion resellers to manage and automatically crosslist their inventory across multiple online marketplaces. This automation saves significant time by eliminating manual listing processes across various sales channels. The service helps businesses increase sales visibility and maintain accurate, synchronized stock levels for efficient operations.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

SID AI builds AI models that embed contextual information to enhance reasoning and decision‑making. Their SID‑1 agentic search model improves embedding accuracy and outperforms leading models on complex retrieval tasks. The company focuses on linking intelligence to real‑world context through advanced search and training techniques.

Sol is a smartphone application that utilizes personality assessments and community connections to enhance users' sense of purpose and fulfillment. By providing personalized wellness tips and facilitating connections with like-minded individuals, Sol addresses the need for holistic well-being in an increasingly disconnected world.

Spinovit developed a method for the quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction. This technology provides a precise assessment of vascular health, addressing the need for reliable diagnostics in cardiovascular disease management.

Sunrise connects React.js job seekers with live video AMAs featuring engineers and recruiters from top companies, facilitating direct interaction and mentorship. This platform addresses the challenge of job acquisition by providing personalized guidance and networking opportunities to help users secure their desired positions.

Telo Therapeutics is developing orally bioavailable nuclear transport inhibitors, specifically TSM74, which targets XPO1 to degrade proteins involved in cancer cell signaling. This approach aims to treat cancers that are resistant to existing therapies, improving safety and efficacy by promoting rapid tumor regression in preclinical models.

ViroVet develops antiviral drugs for treating respiratory diseases in cattle and swine and innovative PLLAV vaccines for viral infections. Their vaccine technology allows for inexpensive, tailor-made modified live virus vaccines that eliminate the cold chain requirement. The company's fast-acting antivirals reduce antibiotic use associated with endemic and epizootic livestock diseases.